tiprankstipranks
Advertisement
Advertisement

ANIP Stock Latest News

ANI Pharmaceuticals Signals Confident 2026 Growth Path
Company AnnouncementsANI Pharmaceuticals Signals Confident 2026 Growth Path
3d ago
ANIP
ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
PremiumCompany Announcements
ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
14d ago
8K
ANIP
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
PremiumCompany Announcements
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
22d ago
8K
ANIP
Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum
PremiumRatings
Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum
25d ago
ANIP
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
PremiumThe Fly
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
27d ago
ANIP
ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34
PremiumThe FlyANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34
27d ago
ANIP
ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
30d ago
ANIP
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
Premium
The Fly
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
2M ago
ANIP
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
PremiumThe Fly
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
2M ago
ANIP
ANI Pharmaceuticals announces publication of iluvien clinical trial results
PremiumThe Fly
ANI Pharmaceuticals announces publication of iluvien clinical trial results
2M ago
ANIP
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors
PremiumCompany Announcements
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors
3M ago
8K
ANIP
ANI Pharmaceuticals Signals Strong Growth in 2025 Call
PremiumCompany Announcements
ANI Pharmaceuticals Signals Strong Growth in 2025 Call
3M ago
ANIP
ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth
PremiumCompany AnnouncementsANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth
3M ago
ANIP
ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98
Premium
The Fly
ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98
3M ago
ANIP
ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64
Premium
The Fly
ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64
3M ago
ANIP
ANIP Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ANIP Upcoming Earnings Report: What to Expect?
3M ago
ANIP
ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
PremiumThe Fly
ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
5M ago
ANIP
ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
PremiumCompany Announcements
ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
5M ago
8K
ANIP
ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
PremiumThe Fly
ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
5M ago
ANIP
ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’
PremiumThe FlyANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’
5M ago
ANIP
ANI Pharmaceuticals Announces Leadership Transition in Board
Premium
Company Announcements
ANI Pharmaceuticals Announces Leadership Transition in Board
6M ago
8K
ANIP
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed
Premium
The Fly
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed
6M ago
ANIP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >